Powder: -20°C for 3 years | In solvent: -80°C for 1 year
LY2334737 是一种具有口服活性的 Gemcitabine 的前药,也是核苷类似物。它抑制肠道病毒 A71 感染,有抗病毒和抗癌活性。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 833 | 现货 | ||
2 mg | ¥ 1,220 | 现货 | ||
5 mg | ¥ 1,830 | 现货 | ||
10 mg | ¥ 2,790 | 现货 | ||
25 mg | ¥ 4,650 | 现货 | ||
50 mg | ¥ 6,630 | 现货 | ||
100 mg | ¥ 8,850 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 1,560 | 现货 |
产品描述 | LY2334737 is an orally available prodrug of gemcitabine with antineoplastic activity. |
体外活性 | Five cell lines that express CES2 responded to LY2334737treatment. LY2334737 was less cytotoxic to a SK-OV-3 CES2 knockdown than parental cells. The drug response of CES2-transfected HCT-116 cells correlated with CES2 expression level. Bystander studies showed statistically greater PC-3-GFP growth inhibition by LY2334737 when cells were cocultured with CES2 and not mock transfectants [1]. |
体内活性 | Oral treatment of xenograft models with 3.2 mg/kg LY2334737 once a day for 21 days showed greater tumor growth inhibition of CES2 transfectant than the mock transfectant (P ≤ 0.001) [1]. The MTD was 40 mg LY2334737. Fatigue was the most frequent DLT for LY2334737monotherapy (4 patients) followed by elevated transaminase levels (2 patients), both observed at the 40- to 50-mg dose levels. Among the 10 patients in the combination arm, 2 had DLTs at the 40-mg dose level. These were fatigue and elevated liver enzyme levels [2]. Metronomic LY2334737 administration caused increased blood flow in luciferase-tagged LM2-4 tumor xenografts, and this effect, readily measured using contrast micro-ultrasound, coincided with a relative increase in tumor bioluminescence [3]. |
分子量 | 389.39 |
分子式 | C17H25F2N3O5 |
CAS No. | 892128-60-8 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 45 mg/mL (115.56 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 2.5681 mL | 12.8406 mL | 25.6812 mL | 64.203 mL |
5 mM | 0.5136 mL | 2.5681 mL | 5.1362 mL | 12.8406 mL | |
10 mM | 0.2568 mL | 1.2841 mL | 2.5681 mL | 6.4203 mL | |
20 mM | 0.1284 mL | 0.642 mL | 1.2841 mL | 3.2101 mL | |
50 mM | 0.0514 mL | 0.2568 mL | 0.5136 mL | 1.2841 mL | |
100 mM | 0.0257 mL | 0.1284 mL | 0.2568 mL | 0.642 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
LY2334737 892128-60-8 Cell Cycle/Checkpoint DNA Damage/DNA Repair Microbiology/Virology Others Nucleoside Antimetabolite/Analog Virus Protease anticancer LY-2334737 HEV Gemcitabine HEVs HRVs EV-A71 Rhinovirus inhibit LY 2334737 Enterovirus HRV orally antiviral Inhibitor inhibitor